lestaurtinib

Action and Spectrum

Action and spectrum:  

The type III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) is target AML.  

FLT3 is important in the development of normal multipotent stem cells and B cells.  

Drug Interaction

Adverse Reaction

Frequency not defined 

Diarrhea 

Nausea 

Vomiting 

Black Box Warning

Black box warning: 

None 

Contraindication / Caution

Contraindications/caution: 

Hypersensitivity 

Severe Hepatic Impairment 

Pregnancy / Lactation

Pregnancy Warnings: 

Pregnancy category: N/A 

Lactation: 

Excretion of the drug into the human breast milk is unknown 

Pregnancy categories: 

Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester. 

Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women. 

Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women. 

Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Adminstartion

Administration: 

Oral administration 

It is administered as oral dosage form.  

Patient Information Leaflet

Patient information leaflet 

Generic Name: lestaurtinib 

Why do we use lestaurtinib? 

lestaurtinib indicated in the treatment of acute myeloid leukemia (AML) and hematological malignancies.